Regulatory & Policy

Shanghai Henlius puts B7H3 bifunctional fusion protein into Phase I testing for advanced solid tumours

Shanghai Henlius Biotech (HKEX: 2696) dosed the first patient in the HLX316 clinical trial, a Phase I first-in-human study evaluating the B7-H3-targeting sialidase Fc fusion protein in patients with advanced or metastatic solid tumours in mainland China. The milestone follows approval of the investigational new drug application by China's National Medical Products Administration in March 2026.

First-in-class mechanism

HLX316 is a heterodimeric biologic constructed from two distinct components joined via a human IgG1 Fc region. The first is an engineered human sialidase Neu2, modified for improved stability and manufacturability relative to the wild-type enzyme. The second is a heavy-chain-only antibody variable domain, or VHH, that binds selectively to B7-H3, a cell-surface protein encoded by the CD276 gene and broadly overexpressed across a wide range of solid tumour types.

The molecule was created by fusing Henlius's proprietary VHH targeting B7-H3 with a sialidase bifunctional fusion protein licensed from Palleon Pharmaceuticals in May 2024, where the compound is also designated E-688. The design is intended to concentrate sialidase enzymatic activity at the surface of B7-H3-expressing tumour cells, driving localised cleavage of sialylated glycans that coat those cells.

That glycan-stripping mechanism sits at the centre of the scientific rationale. Tumours accumulate dense layers of sialic acid-rich carbohydrates on their surface, a process known as hypersialylation, which suppresses both innate immune effectors such as natural killer cells and macrophages, and adaptive T-cell responses. By directing sialidase activity to B7-H3-positive cells, HLX316 is designed to remove this glycocalyx shield locally, restoring immune recognition without triggering systemic immune activation. Preclinical studies cited by Henlius showed potent antigen-directed desialylation on tumour cells in vitro, tumour growth inhibition in humanised mouse models, and no indication of off-target systemic immune effects.

Trial design and objectives

The HLX316 Phase I study registered as NCT07541534 is an open-label, dose-escalation and dose-expansion trial conducted in mainland China. It is structured in two stages. Phase Ia covers dose escalation across five cohorts, ranging from 1.0 mg/kg to 30.0 mg/kg administered once weekly. The lowest cohort uses an accelerated titration design, while the four higher cohorts follow a standard 3+3 escalation scheme. Dose backfill at selected levels is permitted following safety review.

Phase Ib will expand enrolment at dose levels selected on the basis of safety and preliminary efficacy data from Phase Ia, with dosing regimens matched to the corresponding Phase Ia cohorts. The primary objectives are to characterise the safety and tolerability profile of HLX316, establish the maximum tolerated dose and the recommended Phase II dose, and generate an initial read on anti-tumour activity. Primary endpoints include the incidence of dose-limiting toxicities, the maximum tolerated dose and recommended Phase II dose determinations, and objective response rate assessed by the investigator.

The AllSci BriefSystematic R&D and deal news. Daily.

B7-H3 as a cancer therapy target

B7-H3 has attracted sustained interest as an oncology target because of its expression pattern. The protein is expressed at low or undetectable levels in most normal adult tissues but is overexpressed in a broad range of solid tumours, including lung, breast, colorectal, prostate, ovarian, and pediatric cancers, among others. Estimates from the published literature place B7-H3 overexpression in roughly 60% to 70% of solid tumours, a prevalence that substantially exceeds the biomarker frequencies underpinning most currently approved tumour-agnostic therapies.

Despite this prevalence, no B7-H3-targeting agent has received marketing authorization anywhere globally as of the date of the Henlius announcement. The B7-H3 pipeline is active, with antibody-drug conjugates and other modalities in various stages of clinical development at multiple companies, but HLX316 represents a mechanistically distinct approach. Rather than delivering a cytotoxic payload to B7-H3-expressing cells, it deploys enzymatic glycan remodelling to alter the immunosuppressive tumour microenvironment. Henlius describes HLX316 as a potential first-in-class molecule within this mechanistic category.

The Phase I study represents the first clinical evaluation of a B7-H3-targeting sialidase Fc fusion protein in human subjects. Data from the dose-escalation phase will be needed to establish the safety profile and pharmacokinetic characteristics of HLX316 before the programme can advance to the expansion stage and, eventually, disease-specific development. No timeline for Phase Ia data readouts has been disclosed.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article